Latest stories on AUTL
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven
Seeking Alpha58 · neutralearnings
Autolus Therapeutics: Key Questions For The Near Term
Seeking Alpha50 · neutralgeneral
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
Business Insider50 · neutralgeneral
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
GlobeNewswire50 · neutralgeneral
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Business Insider63 · neutralproduct/pr
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
GlobeNewswire56 · neutralproduct/pr
Autolus Therapeutics management to meet virtually with William Blair
The Fly55 · neutralgeneral
Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders
The Fly28 · bearishgeneral
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
Yahoo Top63 · neutralearnings
Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel
The Fly67 · bullishproduct/pr
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Business Insider67 · bullishproduct/pr
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
GlobeNewswire67 · bullishproduct/pr
Autolus Therapeutics Earnings Call Highlights Growth Momentum
TipRanks63 · neutralearnings
Autolus (AUTL) Q2 2026 Earnings Call Transcript
Yahoo Finance73 · bullishearnings
Autolus (AUTL) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
Autolus Therapeutics plc 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Autolus outlines $140M-$150M 2026 AUCATZYL revenue, targets 65%-70% gross margin in 12-18 months
Seeking Alpha67 · bullishproduct/pr
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
AUTL Raises FY26 Guidance as AUCATZYL Revenue Surges 119%—Gross Margins Hit 55% in Q2
August 11, 2026
MarketChameleon73 · bullishearnings
Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
InvestorsHub68 · bullishearnings
Autolus shares rise as Q2 beat and higher AUCATZYL guidance signal launch momentum
Yahoo Finance68 · bullishearnings
Autolus Therapeutics Q2 Earnings Call Highlights
Yahoo Finance63 · neutralearnings
Autolus Lifts 2026 Guidance as AUCATZYL Sales Surge
TipRanks73 · bullishearnings
Autolus Therapeutics plc (AUTL) files 8-K
SEC 8-K50 · neutralgeneral
Autolus Therapeutics Raises Fy26 Revenue View To 140m 150m From 120m 135m
The Fly67 · bullishearnings